Gene therapy

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

REGENXBIO
#Advanced Therapies #Adverse event #FDA #Gene therapy #Hunter Syndrome #Phase I trial #REGENXBIO

FDA pauses REGENXBIO’s gene therapies following tumour discovery

The US Food and Drug Administration (FDA) has placed a clinical hold on REGENXBIO’s investigational gene therapy, RGX-111, for the treatment of MPS I, following a single case of neoplasm (intraventricular CNS tumour) in a participant treated in its Phase I/II study.  The FDA also placed a clinical hold on… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Brain cancer #FDA #Gene therapy #Oncology #Phase I trial #Siren Biotechnology

FDA clears first cancer gene therapy for trials

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma.  … Read More

#Cancer Research #Editor's Choice #News #Regulatory

Gene therapy
#FDA #Gene therapy #Orphan drugs

FDA grants orphan drug designation to MMA treatment 

The US Food and Drug Administration (FDA) has granted orphan drug designation to a treatment for methylmalonic acidaemia (MMA).  GENE202, developed by biotechnology company Genespire, is an in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to treat paediatric patients affected by genetic diseases.  GENE02, which has also been granted orphan drug… Read More

#News #Regulatory

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Cell and gene therapy #FDA #Gene therapy #Rare disease

FDA approves first gene therapy for Wiskott-Aldrich syndrome

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and for whom haematopoietic… Read More

#Editor's Choice #News #Regulatory

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

Stem cell transplant
#Gene therapy #Hunter Syndrome #The University of Manchester

Revolutionary therapy treats Hunter syndrome for first time 

A world-first therapy has provided an unprecedented step towards treating the devastating condition Hunter syndrome.  Researchers at the University of Manchester treated a three-year-old boy, Ollie Chu, with a stem cell gene therapy treatment developed by the university. Several months on from the procedure performed in… Read More

#News

RNA
#Amyotrophic lateral sclerosis (ALS) #Gene therapy #Neurodegenerative disorders #Tel Aviv University

RNA-based gene therapy offers new hope for ALS treatment

A team of researchers have uncovered a previously unknown molecular mechanism that drives the progression of amyotrophic lateral sclerosis (ALS) and succeeded in neutralising it using RNA-based gene therapy.   The study was conducted in the laboratory of Professor Eran Perlson from the Gray Faculty of Medical &… Read More

#Editor's Choice #News

Duchenne muscular dystrophy
#Duchenne muscular dystrophy #Gene editing #Gene mutation #Gene therapy

Duchenne UK hands out £500,000 award to develop DMD therapy 

Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD).  The funding is part of Duchenne UK’s Therapeutic Call, a competitive initiative designed to support innovative research with the potential to deliver new treatments for DMD.  MyoGene Bio… Read More

#Business & Investment #News

CRISPR gene editing
#Cardiovascular disease #Gene editing #Gene therapy #Intellia Therapeutics #Phase III trial

Intellia pauses gene therapy trial due to liver injury

Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.  The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who… Read More

#Editor's Choice #News

Human heart
#AskBio #Gene therapy #Heart failure

Gene therapy could treat congestive heart failure

Gene therapy company AskBio has announced encouraging results from the Phase I trial of gene therapy AB-1002 in participants with congestive heart failure.  The 12-month data set, revealed in Nature Medicine, confirms that meaningful improvements were recorded across several efficacy assessments and no adverse events… Read More

#News

#Breast cancer #DDW Highlights podcast #Drug therapy #Gene therapy #Prostate cancer

DDW Highlights: 21 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed drug therapies could prevent hereditary diseases. Elsewhere, there were… Read More

#Podcasts

#Breast cancer #DNA mutations #Drug therapy #Gene therapy #Prostate cancer #sympos

This week in Drug Discovery (13 – 17 October)

News round-up for 13 – 17 October by Bruno Quinney, Content Team at DDW.  This week’s top story comes from new research showing drug therapies could prevent hereditary diseases. Elsewhere, there have been major developments in cancer research and gene therapy could help combat hearing loss. … Read More

#News